Astria Therapeutics Inc (ATXS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Astria Therapeutics Inc (ATXS) has a cash flow conversion efficiency ratio of -0.138x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.30 Million) by net assets ($233.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Astria Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Astria Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Astria Therapeutics Inc (ATXS) total liabilities for a breakdown of total debt and financial obligations.
Astria Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Astria Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Banco do Estado do Rio Grande do Sul S.A
SA:BRSR3
|
0.283x |
|
Dakota Gold Corp.
NYSE MKT:DC
|
-0.063x |
|
Taewoong Co.Ltd
KQ:044490
|
-0.003x |
|
Tigerair Taiwan Co. Ltd.
TW:6757
|
0.334x |
|
HELL.UNSP.ADR A1 DL-0001
F:1MO
|
N/A |
|
Ningbo Daye Garden Machinery Co Ltd
SHE:300879
|
-0.191x |
|
Empreendimentos Pague Menos S.A
SA:PGMN3
|
0.011x |
|
Ningbo Sinyuan ZM Technology Co. Ltd. A
SHE:301398
|
N/A |
Annual Cash Flow Conversion Efficiency for Astria Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Astria Therapeutics Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see ATXS market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $319.26 Million | $-81.21 Million | -0.254x | +9.65% |
| 2023-12-31 | $243.12 Million | $-68.44 Million | -0.282x | -43.06% |
| 2022-12-31 | $221.22 Million | $-43.53 Million | -0.197x | +20.17% |
| 2021-12-31 | $122.31 Million | $-30.15 Million | -0.247x | +69.14% |
| 2020-12-31 | $40.67 Million | $-32.48 Million | -0.799x | -7.39% |
| 2019-12-31 | $35.72 Million | $-26.57 Million | -0.744x | -10.76% |
| 2018-12-31 | $34.94 Million | $-23.46 Million | -0.672x | +70.49% |
| 2017-12-31 | $11.79 Million | $-26.84 Million | -2.276x | -101.45% |
| 2016-12-31 | $29.09 Million | $-32.86 Million | -1.130x | -91.46% |
| 2015-12-31 | $50.49 Million | $-29.79 Million | -0.590x | -311.17% |
| 2014-12-31 | $-73.05 Million | $-20.41 Million | 0.279x | -10.91% |
| 2013-12-31 | $-52.18 Million | $-16.37 Million | 0.314x | +108.63% |
| 2012-12-31 | $4.29K | $-15.58K | -3.634x | -- |
About Astria Therapeutics Inc
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also devel… Read more